Tools

LEADER 02862cam a2200517 i 4500

001 ocn799785338;

003 OCoLC;

005 20200121081744.0;

006 m o d f ;

007 cr gn|||||||||;

008 120715s1998 dcua ob f000 0 eng c;

019 a| 652419830a| 654154202a| 805938918a| 1011893402a| 1022043481a| 1049952669a| 1069624924;

035 a| (Sirsi) o799785338;

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

050 4 a| KF27b| .G663 1996j;

074 a| 1016-C (online);

086 0 a| Y 4.G 74/7:OF 2/6;

245 10 a| Off-label drug use and FDA review of supplemental drug applications :b| hearing before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, second session, September 12, 1996.;

264 1 a| Washington :b| U.S. Government Printing Office,c| 1998.;

300 a| 1 online resource (iii, 152 pages) :b| illustrations;

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

504 a| Includes bibliographical references.;

500 a| GPO Cataloging Record Distribution Program (CRDP).;

588 a| Description based on online resource; title from PDF title page (govinfo, viewed May 2, 2019).;

610 10 a| United States.b| Food and Drug Administrationv| Rules and practice.=| ^A1253;

650 0 a| Off-label drug usez| United States.=| ^A1389335;

650 0 a| Drug approvalz| United States.=| ^A1001108;

650 0 a| Drugsx| Side effectsz| United States.=| ^A1404;

650 12 a| Off-Label Use0| (DNLM)D056687=| ^A1337609;

650 7 a| Drugsx| Labeling.2| fast0| (OCoLC)fst00898826;

651 7 a| United States.2| fast0| (OCoLC)fst01204155?| UNAUTHORIZED;

655 7 a| Legislative hearings.2| lcgft;

776 08 i| Print version:a| United States. Congress. House. Committee on Government Reform and Oversight. Subcommittee on Human Resources and Intergovernmental Relations.t| Off-label drug use and FDA review of supplemental drug applicationsw| (DLC) 98133428w| (OCoLC)38469061;

856 40 u| https://purl.fdlp.gov/GPO/gpo119756;

949 a| Click on web addressw| asish| joyner94;

596 a| 1;

998 a| 5101512;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 5101512-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 6/13/2019x| EDOCUMENTz| JERESOURCE;

Off-label drug use and FDA review of supplemental drug applications : hearing before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, second session, September 12, 1996.

Author/creator	United States
Format	Electronic
Publication	Washington : U.S. Government Printing Office, 1998.
Description	1 online resource (iii, 152 pages) : illustrations
Supplemental Content	https://purl.fdlp.gov/GPO/gpo119756
Subjects	United States. Food and Drug Administration--Rules and practice. Off-label drug use--United States. Drug approval--United States. Drugs--Labeling. --Government policy. --United States. Drugs--Side effects. --United States. Off-Label Use

General note	GPO Cataloging Record Distribution Program (CRDP).
Bibliography note	Includes bibliographical references.
Source of description	Description based on online resource; title from PDF title page (govinfo, viewed May 2, 2019).
Issued in other form	Print version: United States. Congress. House. Committee on Government Reform and Oversight. Subcommittee on Human Resources and Intergovernmental Relations. Off-label drug use and FDA review of supplemental drug applications
Genre/form	Legislative hearings.
GPO item number	1016-C (online)
Govt. docs number	Y 4.G 74/7:OF 2/6

Availability

Library	Location	Call Number	Status	Item Actions
	Electronic Resources	Access Content Online	✔ Available

Off-label drug use and FDA review of supplemental drug applications : hearing before the Subcommittee on Human Resources and Intergovernmental Relations of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fourth Congress, second session, September 12, 1996.

Click here for more information about this title

Availability